Sign In
Last checked at 
30 Mar 2009 12:59
Avacta Group plc Director's Shareholding Avacta Group plc (the "Company") announces that it has received notificationthat on 27 March 2009, Alan Aubrey, a director of the Company, sold 4,385,000ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares"),and purchased within his SIPP 4,345,000 ordinary shares at 2 pence per share.Following this transaction, Alan Aubrey is beneficially interested in12,133,419 Ordinary Shares, representing 1.09% of the issued share capital ofthe Company. 30 March 2009Enquiries:Haggie Financial LLP Tel: 020 7417 8989 Nicholas Nelson/Kathy Boate Kathy.boate@haggie.co.uk Nominated Advisor: Tel: 020 7776 6550 Daniel Stewart & Company plc
Lindsay Mair/Charlotte Stranner
www.danielstewart.co.uk Novum Securities Limited Tel: 020 7562 4700 Henry Turcan Notes to Editors:About Avacta:
Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets.
Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in clinical diagnostics are also being targeted for these core bio-analytical technologies and for Avacta's trace gas analysis technology as well as opportunities in industrial and military sensing applications.
A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Limited, which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta joined AIM in August 2006.
vendor
Follow the stocks
